Recent studies have confirmed the long-term safety and efficacy of laparoscopic distal gastrectomy compared to open gastrectomy for locally advanced gastric cancer. Ongoing trials are evaluating perioperative immunotherapy for resectable gastric cancers. Key trials like dante, gercor neonipiga, keynote-859, and spotlight are exploring targeted therapies for unresectable or metastatic gastroesophageal cancers, incorporating immune checkpoint inhibitors and the monoclonal antibody zolbetuximab targeting cldn18.2.
Journal Article by Mullen JT in Ann Surg Oncol
© 2024. Society of Surgical Oncology.